Taiwan Liposome OA therapy hits mark in Phase II trial

Months after proposing a second listing on NASDAQ, Taiwan Liposome Co. Ltd. (TPEx:4152) said the lower of two doses of its lead candidate TLC599

Read the full 241 word article

User Sign In